Search

Displaying results 4951 - 4960 of 10000 in total
  1. Drug

    PN0621

    go.drugbank.com/drugs/DB05218
    Experimental

    It is being developed by Peptech. … PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis.

  2. Drug

    SOR-C13

    go.drugbank.com/drugs/DB15366
    Investigational

    SOR-C13 is under investigation in clinical trial NCT01578564 (Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel).

    Categories: Ion Channels
  3. Drug

    BCc1

    go.drugbank.com/drugs/DB16504
    Experimental

    BCc1 is a nanomedicine that demonstrated potent anticancer effects in both in vitro and in vivo studies.

  4. Drug

    Honey

    go.drugbank.com/drugs/DB14242
    ApprovedInvestigational

    Honey is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.

  5. Drug

    Gosogliptin

    go.drugbank.com/drugs/DB08382
    Investigational

    Gosogliptin has been used in trials studying the treatment of Renal Insufficiency, Chronic.

    Categories: DPP-IV Inhibitors
  6. Drug

    ARQ 171

    go.drugbank.com/drugs/DB06034
    Investigational

  7. Drug

    Bromopride

    go.drugbank.com/drugs/DB09018
    Investigational

    Bromopride is a dopamine antagonist used as an antiemetic. Its prokinetic properties are similar to those of metoclopramide. It is unavailable in America or the United Kingdom.

    Synonyms: 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide
  8. Drug

    Quinacrine

    go.drugbank.com/drugs/DB01103
    Investigational

    It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2. … An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years.

  9. Drug

    Blonanserin

    go.drugbank.com/drugs/DB09223
    Investigational

    Blonanserin is an atypical antipsychotic approved in Japan in January, 2008. … As a second-generation (atypical) antipsychotic, it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics.

  10. Drug

    Dimethylcurcumin

    go.drugbank.com/drugs/DB06133
    Investigational

    Dimethylcurcumin is a synthetic chemical compound that is loosely based on a compound found in curcumin. It is a novel anti-androgen that enhances androgen receptor degradation.